Table 3

HLA-F allelic and genotypic frequencies in patients with HLA-B27 AS and HLA-B27 controls

HLA-B27 Portuguese patients with ASHLA-B27 Portuguese unaffected controls
Alleles FAs Fc P values pCA Bonferroni OR (95% CI)
F*01:01:01 0.540.520.591.08 (0.83 to 1.41)
F*01:01:02 0.140.210.0050.010.60 (0.42 to 0.86)
F*01:01:03 0.130.130.921.02 (0.69 to 1.52)
F*01:03:01 0.180.130.040.081.48 (1.03 to 2.13)
F*01:04 0.010.011.000.85 (0.19 to 3.82)
Genotypes FAs Fc P values Bonferroni OR (95% CI)
F*01:01:01/F*01:01:01 0.300.301.001.01 (0.67 to 1.51)
F*01:01:01/F*01:01:02 0.140.200.080.63 (0.38 to 1.05)
F*01:01:01/F*01:01:03 0.150.140.791.12 (0.66 to 1.90)
F*01:01:01/F*01:03:01 0.190.110.010.042.01 (1.17 to 3.44)
F*01:01:01/F*01:04 0.0050.0041.001.14 (0.07 to 18.25)
F*01:01:02/F*01:01:02 0.050.040.651.27 (0.51 to 3.20)
F*01:01:02/F*01:01:03 0.010.060.020.080.25 (0.07 to 0.89)
F*01:01:02/F*01:03:01 0.030.080.010.040.32 (0.13 to 0.82)
F*01:01:02/F*01:04 0.000.0041.000
F*01:01:03/F*01:01:03 0.050.010.030.114.33 (1.19 to 15.75)
F*01:01:03/F*01:03:01 0.020.030.590.70 (0.23 to 2.18)
F*01:01:03/F*01:04 0.00000.0041.000
F*01:03:01/F*01:03:01 0.040.020.242.32 (0.69 to 7.81)
F*01:03:01/F*01:04 0.010.0040.602.28 (0.21 to 25.33)
SNP Alleles AS MAF C MAF P values pCA Bonferroni OR (95% CI)
rs2075682T/A0.120.210.00040.00080.53 (0.37 to 0.75)
rs17875380A/C0.0070.010.550.65 (0.15 to 2.72)
rs1736924C/T0.180.130.030.0591.48 (1.03 to 2.13)
rs1736922T/C0.150.140.791.05 (0.73 to 1.52
SNP Alleles AS MAF C MAF P values pCA OR (95% CI)
rs2075682T/A0.110.140.100.110.75 (0.54 to 1.06)
rs17875380A/C0.0070.0081.000.780.83 (0.23 to 3.04)
rs1736924C/T0.170.171.000.991.00 (0.75 to 1.34)
rs1736922T/C0.180.210.270.250.85 (0.65 to 1.13)
  • AS, ankylosing spondylitis; AAS MAF, minor allele frequency in AS patient group; Bonferroni, Bonferroni corrected p value; C MAF, minor allele frequency in control group; FAs, frequency in patient group; Fc, frequency in control group; P value, Fisher’s exact test; pCA, Cochrane-Armitage test of trend; SNP, single nucleotide polymorphism.